Cataplexy clinical trials
The registry lists 35 studies for Cataplexy across more than 10 countries. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-11.
Status
- Completed
- 25
- Recruiting
- 5
- No longer available
- 1
- Status unknown
- 1
- Not yet recruiting
- 1
- Terminated
- 1
Phase
- Phase 3
- 15
- Phase 2
- 9
- Phase 1
- 4
- Phase 4
- 1
Where
- United States
- 24
- Canada
- 8
- France
- 8
- Belgium
- 4
- Australia
- 4
- Spain
- 3
Who runs them
Bioprojet (4) · Axsome Therapeutics, Inc. (3) · NLS Pharmaceutics (3) · Alkermes, Inc. (2) · Suven Life Sciences Limited (2) · Jazz Pharmaceuticals (2) · Avadel (2) · Harmony Biosciences Management, Inc. (2)
Studies
Recruiting first, then most recently updated. Showing 35 of 35 — search for more.
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of HypersomnolenceRecruitingNCT07598708Phase 2/31 country
- A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)RecruitingNCT07540364Phase 31 country
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1RecruitingNCT07455383Phase 39 countries
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With NarcolepsyRecruitingNCT07675135Phase 32 countries
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931682 countries
- A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1Not yet recruitingNCT05914194Phase 3
- Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With HypersomnolenceCompletedNCT05615584Not applicable1 country
- Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)CompletedNCT03881852Phase 21 country
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)CompletedNCT06358950Phase 28 countries
- A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyCompletedNCT05059223Phase 32 countries
- A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)CompletedNCT05113745Phase 32 countries
- An Open Label Study of FT218 in Subjects With NarcolepsyCompletedNCT04451668Phase 32 countries
- A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without CataplexyCompletedNCT04072380Phase 22 countries
- Awareness and Self-Compassion Enhancing Narcolepsy TreatmentCompletedNCT04306952Not applicable1 country
- This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.CompletedNCT05015673Phase 11 country
- Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic HypersomniaCompletedNCT03772314Phase 21 country
- An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With NarcolepsyCompletedNCT05055024Phase 21 country
- Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of NarcolepsyCompletedNCT04923594Phase 21 country
- Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine ChangesCompletedNCT00345800Phase 11 country
- Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyCompletedNCT02720744Phase 36 countries
- Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without CataplexyTerminatedNCT03198156Not applicable1 country
- Xyrem and Brain Dopamine in NarcolepsyCompletedNCT02637076Phase 41 country
- A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With CataplexyCompletedNCT03030599Phase 36 countries
- 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'SuspendedNCT044197921 country
- Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without CataplexyNo longer availableNCT034331311 country
- A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With CataplexyCompletedNCT02221869Phase 34 countries
- A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2CompletedNCT02512588Phase 21 country
- Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior DisorderStatus unknownNCT03425214Not applicable1 country
- Flumazenil for the Treatment of Primary HypersomniaCompletedNCT01183312Phase 1/21 country
- Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)CompletedNCT01399606Phase 31 country
- Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)CompletedNCT01800045Phase 31 country
- Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With NarcolespyCompletedNCT01067235Phase 31 country
- Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in NarcolepsyCompletedNCT01067222Phase 31 country
- Single-dose Safety Study of APD916 in Healthy VolunteersCompletedNCT01093508Phase 11 country
- Provigil (Modafinil) Study by Taiwan Biotech Co.CompletedNCT00174174Not applicable